Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 27 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine if baseline subgroups in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial can be identified for whom intensive compared with standard glycemia treatment had different effects on all-cause mortality. RESEARCH DESIGN AND METHODS: Exploratory post hoc intention-to-treat comparisons were made between intensive and standard glycemia groups on all-cause mortality by subgroups defined by baseline characteristics. RESULTS: There were few significant interactions between baseline characteristics and effects of intensive versus standard glycemia treatment on mortality: self-reported history of neuropathy (hazard ratio [HR] 1.95, 95% CI 1.41–2.69) versus no history of neuropathy (0.99, 0.79–1.26; P value for interaction 0.0008), higher A1C (A1C >8.5%: HR 1.64, 95% CI 1.22–2.22; A1C 7.5–8.4%: 1.00, 0.75–1.34; A1C <7.5%: 1.00, 0.67–1.50; P value for interaction 0.04), and aspirin use (HR 1.45, 95% CI 1.13–1.85, compared with 0.96, 0.72–1.27, in nonusers; P value for interaction 0.03). CONCLUSIONS: We found a remarkable similarity of effect from intensive compared with standard glycemia treatment on mortality across most baseline subgroups. No differential effect was found in subgroups defined by variables anticipated to have an interaction: age, duration of diabetes, and previous history of cardiovascular disease. The three baseline characteristics that defined subgroups for which there was a differential effect on mortality may help identify patients with type 2 diabetes at higher risk of mortality from intensive regimens for glycemic control. Further research is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 1×
“Adding to the controversy were results of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and Veterans Affairs Diabetes Trial (VADT), demonstrating that although there was no significant reduction in the primary end point of CVD events, there was no increase in mo…”
ResultHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“Adding to the controversy were results of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and Veterans Affairs Diabetes Trial (VADT), demonstrating that although there was no significant reduction in the primary end point of CVD events, there was no increase in mo…”
ResultStandards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445 · cited 1×
“Analyses were conducted using intention-to-treat comparisons between the intensive glycemia and standard groups on the mortality rate within each subgroup as defined in Table 1 above (15).”
MethodFeldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293 · cited 1×
“Complete details of the study design and conduct have been previously published (13,14).”
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Young, L. H., Wackers, F. J. T., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009) · JAMA · doi:10.1001/jama.2009.476 · Cited by 809
Cited by
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Selvarajah, D., Kar, D., Khunti, K., Davies, M. J., Scott, A. R., Walker, J., & Tesfaye, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30081-6 · Cited by 556
Bozkurt, B., Aguilar, D., Deswal, A., Dunbar, S. B., Francis, G. S., Horwich, T., Jessup, M., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 522
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487
Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
Ismail-Beigi, F., Moghissi, E., Tiktin, M., Hirsch, I. B., Inzucchi, S. E., & Genuth, S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00007 · Cited by 386
“The ACCORD trial reported a trend toward lower all-cause mortality among participants younger than 65 years at baseline who were randomly assigned to receive standard treatment (13), whereas the ADVANCE trial reported lower rates of combined major macro- and microvascular events in younger participants in the intensiv…”
ResultSelf-citationDiabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease
Vinik, A. I., Erbas, T., & Casellini, C. M. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12042 · Cited by 371
Challenges of neuropathic pain: focus on diabetic neuropathy
Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., & Treede, R.-D. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02145-7 · Cited by 325
Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials
Ang, L., Jaiswal, M., Martin, C., & Pop-Busui, R. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0528-7 · Cited by 303
Self-citationHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 291
Pharmacological treatment of hyperglycemia in type 2 diabetes
Taylor, S. I., Yazdi, Z. S., & Beitelshees, A. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142243 · Cited by 245
Epidemiology of polyneuropathy in diabetes and prediabetes
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-53480-4.00001-1 · Cited by 235
“All rights reserved significant predictor for increased mortality in type 2 diabetic subjects allocated to a very intensive diabetes therapy aimed at HbA1c<6.0% in the ACCORD trial (Calles-Escandón et al., 2010).”
BackgroundInfluentialHempe, J. M., Liu, S., Myers, L., McCarter, R. J., Buse, J. B., & Fonseca, V. (2015) · Diabetes Care · doi:10.2337/dc14-1844 · Cited by 233
“associated with intensive treatment in ACCORD (16,17).”
Self-citationNolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O., & Prentki, M. (2015) · Diabetes · doi:10.2337/db14-0694 · Cited by 226
“These analyses revealed, however, that a higher HbA1c at baseline and a failure to improve average HbA1c throughout the study despite intensive therapy were linked to increased mortality (44,45).”
ResultPapademetriou, V., Lovato, L., Doumas, M., Nylen, E., Mottl, A., Cohen, R. M., Applegate, W. B., Puntakee, Z., Yale, J. F., & Cushman, W. C. (2015) · Kidney International · doi:10.1038/ki.2014.296 · Cited by 210
Self-citationRisk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015
Papanas, N., & Ziegler, D. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.48 · Cited by 207
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub3 · Cited by 203
RetractedZiegler, D., Tesfaye, S., Spallone, V., Gurieva, I., Al Kaabi, J., Mankovsky, B., Martinka, E., Radulian, G., Nguyen, K. T., Stirban, A. O., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109063 · Cited by 196
Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes
The ACCORD Study Group (2016) · Diabetes Care · doi:10.2337/dc15-2283 · Cited by 193
“5% at baseline (20), or in the subgroup with the highest discrepancy between baseline HbA1c and the HbA1c levels that would be predicted from fasting plasma glucose levels (due to higher protein glycation, higher prandial glucose levels, or other reasons) (21).”
BackgroundStrength Training as a Countermeasure to Aging Muscle and Chronic Disease
Hurley, B. F., Hanson, E. D., & Sheaff, A. K. (2011) · Sports Medicine · doi:10.2165/11585920-000000000-00000 · Cited by 140
Understanding Diabetic Neuropathy: Focus on Oxidative Stress
Pang, L., Lian, X., Liu, H., Zhang, Y., Li, Q., Cai, Y., Ma, H., & Yu, X. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9524635 · Cited by 184
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
Home, P., Riddle, M., Cefalu, W. T., Bailey, C. J., Bretzel, R. G., del Prato, S., Leroith, D., Schernthaner, G., van Gaal, L., & Raz, I. (2014) · Diabetes Care · doi:10.2337/dc13-2743 · Cited by 167
“5%), any prior history of neuropathy, and current aspirin use (51).”
BackgroundYang, H., Sloan, G., Ye, Y., Wang, S., Duan, B., Tesfaye, S., & Gao, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00929 · Cited by 151
Duckworth, W. C., Abraira, C., Moritz, T. E., Davis, S. N., Emanuele, N., Goldman, S., Hayward, R., Huang, G. D., Marks, J. B., Reaven, P. D., et al. (2011) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.10.003 · Cited by 152
Tavakoli, M., Kallinikos, P. A., Iqbal, A., Herbert, A., Fadavi, H., Efron, N., Boulton, A. J. M., & Malik, R. A. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03372.x · Cited by 151
Rosenstock, J., Marx, N., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Bluhmki, E., Patel, S., Johansen, O.-E., & Woerle, H.-J. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112475102 · Cited by 144
Pratley, R. E., Tuttle, K. R., Rossing, P., Rasmussen, S., Perkovic, V., Nielsen, O. W., Mann, J. F. E., MacIsaac, R. J., Kosiborod, M. N., Kamenov, Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.004 · Cited by 132
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.016 · Cited by 148
Vinik, A. I., & Erbas, T. A. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53491-0.00022-5 · Cited by 168
Current concepts in the management of diabetic polyneuropathy
Ziegler, D., Παπάνας, Ν., Schnell, O., Nguyen, B. D., Nguyen, K. T., Kulkantrakorn, K., & Deerochanawong, C. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13401 · Cited by 171
Imran, S. A., Agarwal, G., Bajaj, H. S., & Ross, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.030 · Cited by 113
Giorgino, F., Leonardini, A., & Laviola, L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12044 · Cited by 118
Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study
Elder, D. H. J., Singh, J. S. S., Levin, D., Donnelly, L. A., Choy, A.-M., George, J., Struthers, A. D., Doney, A. S. F., & Lang, C. C. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.455 · Cited by 109
Riddle, M. C. (2010) · Circulation · doi:10.1161/circulationaha.110.960138 · Cited by 110
Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions
Javed, S., Alam, U., & Malik, R. A. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.63 · Cited by 101
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 95
Neuropathy: The Crystal Ball for Cardiovascular Disease?
Vinik, A. I., Maser, R. E., & Ziegler, D. (2010) · Diabetes Care · doi:10.2337/dc10-0745 · Cited by 84
“In the ACCORD study (8), the Michigan Neuropathy Screening Instrument (MNSI) detected peripheral neuropathy in 4,357 patients, whereas only 2,737 reported a history of neuropathy.”
BackgroundResultInfluentialIs Hyperglycemia a Cardiovascular Risk Factor?
Pistrosch, F., Natali, A., & Hanefeld, M. (2011) · Diabetes Care · doi:10.2337/dc11-s207 · Cited by 81
“, congestive heart failure and albuminuria/renal impairment or neuropathy (25).”
BackgroundWang, C. C. L., & Reusch, J. E. B. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.036 · Cited by 82
Ziegler, D., Low, P. A., Freeman, R. L., Tritschler, H., & Vinik, A. I. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.018 · Cited by 89
Hemmingsen, B., Lund, S. S., Gluud, C. N., Vaag, A. A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub2 · Cited by 94
RetractedCardiovascular Disease in Diabetes: Where Does Glucose Fit In?
Reusch, J. E. B., & Wang, C. C. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-3011 · Cited by 68
Intensive versus conventional glycaemic control for treating diabetic foot ulcers
Fernando, M. E., Seneviratne, R. M., Tan, Y. M., Lazzarini, P. A., Sangla, K. S., Cunningham, M., Buttner, P. G., & Golledge, J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010764.pub2 · Cited by 80
Shah, H. S., Gao, H., Morieri, M. L., Skupien, J., Marvel, S., Paré, G., Mannino, G. C., Buranasupkajorn, P., Mendonca, C., Hastings, T., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0285 · Cited by 60
“5% [69 mmol/mol], presence of neuropathy, and aspirin use at baseline) (7) did not attenuate the effect of”
Backgroundvan Steen, S. C. J., Schrieks, I. C., Hoekstra, J. B. L., Lincoff, A. M., Tardif, J., Mellbin, L., Rydén, L., Grobbee, D. E., DeVries, J. H., & on behalf of the AleCardio study group (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317692664 · Cited by 59
The Conductor of the Autonomic Orchestra
Vinik, A. I. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00071 · Cited by 67
Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients
Moțățăianu, A., Maier, S., Bajkó, Z., Voidăzan, S. T., Bălașa, R., & Stoian, A. (2018) · BMC Neurology · doi:10.1186/s12883-018-1125-1 · Cited by 62
Clinical Implications of the ACCORD Trial
Genuth, S., & Ismail-Beigi, F. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1679 · Cited by 56
Self-citationMattila, T., & de Boer, A. (2010) · Drugs · doi:10.2165/11585220-000000000-00000 · Cited by 69
The Role of Biofactors in Diabetic Microvascular Complications
Ziegler, D., Porta, M., Παπάνας, Ν., Moța, M., Jermendy, G., Beltramo, E., Mazzeo, A., Caccioppo, A., Striglia, E., Serhiyenko, V. A., et al. (2021) · Current Diabetes Reviews · doi:10.2174/1871527320666210825112240 · Cited by 61
Wherefore Art Thou, O Treatment for Diabetic Neuropathy?
Malik, R. A. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.03.008 · Cited by 55
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P., & Tuomilehto, J. O. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 57
Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes
Riddle, M. C., & Karl, D. M. (2012) · Diabetes Care · doi:10.2337/dc12-0650 · Cited by 51
Ziegler, D., Strom, A., Lobmann, R., Reiners, K., Rett, K., & Schnell, O. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.09.008 · Cited by 48
García-Alcalá, H., Vichido, C. I. S., Macedo, S. I., Genestier-Tamborero, C. N., Palacios, M. M., Hirales-Tamez, O., García, C. P., & Ziegler, D. (2015) · Journal of Diabetes Research · doi:10.1155/2015/189857 · Cited by 53
Pathways in the Diagnosis and Management of Diabetic Polyneuropathy
Kaku, M. C., Vinik, A. I., & Simpson, D. M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0609-2 · Cited by 52
Durán, A. M., Salto, L., Camara, J. R., Basu, A., Perez‐Paquien, I., Beeson, W. L., Firek, A. F., Cordero‐MacIntyre, Z., & León, M. A. D. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s187268 · Cited by 45
Determinants of mortality in patients with type 2 diabetes: a review
Engelmann, J., Manuwald, U., Rubach, C., Kügler, J., Birkenfeld, A. L., Hanefeld, M., & Rothe, U. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9349-0 · Cited by 44
Changes in body mass index and waist circumference and heart failure in type 2 diabetes mellitus
Zhou, Y., Chai, X., Yang, G., Sun, X., & Xing, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1305839 · Cited by 38
“This trial ’ s design and main study outcomes have been previously published (14, 15).”
BackgroundEmerging drugs for diabetic peripheral neuropathy and neuropathic pain
Παπάνας, Ν., & Ziegler, D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1257605 · Cited by 38
“Importantly, both DSPN [8,9] and Charcot osteoarthropathy [10,11] may be associated with increased mortality.”
BackgroundAroda, V. R., & Eckel, R. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14830 · Cited by 43
Nasir, S., & Aguilar, D. A. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.031 · Cited by 45
Pfister, R., Sharp, S. J., Luben, R., Khaw, K., & Wareham, N. J. (2011) · Diabetologia · doi:10.1007/s00125-011-2162-0 · Cited by 33
“However, recent post hoc analyses of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial also suggested that a subgroup of patients with refractory hyperglycaemia accounts for the increased mortality risk observed with the intensive treatment strategy in diabetic patients and not ordinary lower glycae…”
ResultZiegler, D., Schleicher, E. D., Strom, A., Knebel, B., Fleming, T. H., Nawroth, P. P., Häring, H., Παπάνας, Ν., Szendrödi, J., Müssig, K., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2811 · Cited by 34
“Diabetic sensorimotor polyneuropathy (DSPN) is a serious complication of diabetes encountered in about one-third of all diabetic patients [1] and predictor of feared endpoints such as diabetic foot ulcers [2], cardiovascular morbidity [3], and mortality [4].”
BackgroundCardiac Autonomic Testing and Treating Heart Disease. “A Clinical Perspective”
DePace, N. L., Mears, J. P., Yayac, M. F., & Colombo, J. (2014) · Heart International · doi:10.5301/heartint.5000216 · Cited by 31
de Vries, T. I., Dorresteijn, J. A. N., van der Graaf, Y., Visseren, F. L. J., & Westerink, J. (2019) · Diabetes Care · doi:10.2337/dc19-0776 · Cited by 31
State-of-the-art pharmacotherapy for diabetic neuropathy
Azmi, S., Alam, U., Burgess, J., & Malik, R. A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1812578 · Cited by 32
The bigger, the better? When multicenter clinical trials and meta-analyses do not work
Seifirad, S., & Alquran, L. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1860922 · Cited by 30
Cardiac Autonomic Testing and Diagnosing Heart Disease. “A Clinical Perspective”
DePace, N. L., Mears, J. P., Yayac, M. F., & Colombo, J. (2014) · Heart International · doi:10.5301/heartint.5000218 · Cited by 33
“For example, more is not always better, such as intensive glucose control for diabetic patients (55-57).”
BackgroundNahmias, A., Stahel, P., Xiao, C., & Lewis, G. F. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00100 · Cited by 31
Glycemic Control and Cardiovascular Disease: What’s a Doctor to Do?
Kishore, P., Kim, S. H., & Crandall, J. P. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0268-5 · Cited by 33
“Subgroup analysis from ACCORD suggested that patients without a previous cardiovascular event and those with lower baseline HbA1c did show benefit from intensive glucose management [14, 64].”
MethodLi, J., Dong, Y., Wu, T., & Tong, N. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12361 · Cited by 29
The ECG Vertigo in Diabetes and Cardiac Autonomic Neuropathy
Voulgari, C., Tentolouris, N., & Stefanadis, C. (2011) · Experimental Diabetes Research · doi:10.1155/2011/687624 · Cited by 25
Are Glucose Readings Sufficient to Adjust Insulin Dosage?
Bashan, E., Herman, W. H., & Hodish, I. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0112 · Cited by 22
Prazeres, F., & de Figueiredo, D. M. P. (2014) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-13-68 · Cited by 28
“Although HbA1c below 7% is recommended for the general diabetic population, this value has been questioned for the elderly diabetics and those with comorbidities [29,30].”
BackgroundPoint: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding?
Lachin, J. M. (2010) · Diabetes Care · doi:10.2337/dc10-1506 · Cited by 20
“The Action to Control CardiovascularRisk in Diabetes (ACCORD) studywas designed to assess whether intensive glucose management aimed at a normal A1C ( 6”
BackgroundKirsh, S. R., & Aron, D. C. (2011) · Drugs & Aging · doi:10.2165/11594750-000000000-00000 · Cited by 17
Kloecker, D. E., Khunti, K., Davies, M. J., Pitocco, D., & Zaccardi, F. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.08.047 · Cited by 17
Vinik, A. I., Bloom, H. L., & Colombo, J. (2014) · Heart International · doi:10.5301/heart.2014.12495 · Cited by 17
Bloom, H. L., Vinik, A. I., & Colombo, J. (2014) · Heart International · doi:10.5301/heart.2014.12496 · Cited by 16
“The importance of autonomic assessment is emphasized by the current reports from the DIAD study (28) and the ACCORD study (29, 30).”
BackgroundDiabetic Peripheral and Autonomic Neuropathy
Ziegler, D. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch40 · Cited by 16
Twiddy, H., Frank, B., & Alam, U. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00983-y · Cited by 15
Hypoglycemia in Type 2 Diabetes: Current Controversies and Changing Practices
Bloomgarden, Z. T., & EINHORN, D. F. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00066 · Cited by 15
Glycemic control and cardiovascular mortality
Riddle, M. C. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283446b7e · Cited by 19
Kim, I., Williams, R. H., Schutzler, S. E., Lasley, C. J., Bodenner, D., Wolfe, R. R., & Coker, R. H. (2014) · Nutrition & Metabolism · doi:10.1186/1743-7075-11-49 · Cited by 16
Kadowaki, T., Ohtani, T., & Odawara, M. (2012) · Diabetology International · doi:10.1007/s13340-012-0087-6 · Cited by 14
“Several subanalyses of data from randomized controlled trials showed that patients with lower HbA1c, shorter diabetes duration, and fewer microvascular complications at the time of insulin therapy initiation were more likely to have a lower risk of macrovascular complications when given intensive therapy including ins…”
BackgroundIs HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old?
Bloomgarden, Z. T., EINHORN, D. F., & Handelsman, Y. (2017) · Diabetes Care · doi:10.2337/dci16-0043 · Cited by 16
“Yehuda Handelsman4 D IA B ET ES A N D A G IN G also a trend to increased hypoglycemia frequency at HbA1c .9% (7), a pattern similar to that seen in ACCORD (8).”
BackgroundInfluentialControl of Postprandial Glucose Levels with Insulin in Type 2 Diabetes
Blevins, T. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2313 · Cited by 17
“4%) at baseline and patients with no prior CVD had improved outcome on CVD endpoints with intensive therapy.(8) In ADVANCE, intensive glycemic control improved microvascular complications, such as nephropathy, but had no signifi cant effect on macrovascular events.”
BackgroundRiddle, M. C., & Gerstein, H. C. (2015) · Diabetes Care · doi:10.2337/dc15-1073 · Cited by 15
“5% during ongoing treatment (2), 2) failed to reduce HbA1c more than 0.”
BackgroundBloomgarden, Z. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12065 · Cited by 13
The Role of Platelets in Hypoglycemia-Induced Cardiovascular Disease: A Review of the Literature
Ali, A. A. G., Niinuma, S. A., Moin, A. S. M., Atkin, S. L., & Butler, A. E. (2023) · Biomolecules · doi:10.3390/biom13020241 · Cited by 14
Pritchard, N., Edwards, K. P., Dehghani, C., Fadavi, H., Jeziorska, M., Marshall, A. G., Petropoulos, I. N., Ponirakis, G., Russell, A. W., Sampson, G. P., et al. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.02.011 · Cited by 14
Ziegler, D., Winter, K., Strom, A., Zhivov, A., Allgeier, S., Παπάνας, Ν., Ziegler, I., Brüggemann, J., Ringel, B., Peschel, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173832 · Cited by 13
Gomes, D., Presume, J., Gonçalves, P. D. A., Almeida, M., Mendes, M., & Ferreira, J. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07547-3 · Cited by 18
“However, a variety of strategies that intensified glycemic control failed to demonstrate reductions in ASCVD compared to a more conservative approach [4–6].”
Odawara, M., Kadowaki, T., & Naito, Y. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.09.012 · Cited by 12
“Studies in Western population postulate that in patients with existing microvascular complications and inadequate glycemic control, it is difficult to achieve strict glycemic control due to the risk of worsening the complications or cardiovascular events (Calles-Escandon et al., 2010; Patel et al., 2008; The Diabetes…”
BackgroundImpact of glycemic control over cardiac autonomic neuropathy
Meher, M., & Panda, J. K. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00653-7 · Cited by 11
Poulose, S., Cheriyan, E., Poulose, A., Cheriyan, R., Vadakkanezath, B., & Ziemer, P. (2014) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163514561055 · Cited by 11
Charles, M., Simmons, R. K., Williams, K. M., Roglić, G., Sharp, S. J., Kinmonth, A., Wareham, N. J., & Griffin, S. J. (2012) · British Journal of General Practice · doi:10.3399/bjgp12x649070 · Cited by 11
Team-Based Care for Managing Noncardiac Conditions in Patients with Heart Failure
Vader, J. M., & Rich, M. W. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.03.006 · Cited by 10
Pafili, K., Trypsianis, G., Papazoglou, D., Maltezos, E. S., & Παπάνας, Ν. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180829120101 · Cited by 10
Metadata
- Authors
- Calles-Escandón, J., Lovato, L. C., Simons-Morton, D. G., Kendall, D. M., Pop-Busui, R., Cohen, R. M., Bonds, D. E., Fonseca, V. A., Ismail-Beigi, F., Banerji, M. A., Failor, A., & Hamilton, B.
- Affiliations
- Wake Forest University Health Sciences (US)
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland;
- Park Nicollet Health Services (US)
- Department of Endocrinology, Metabolism, and Nutrition, University of Michigan Medical School, Ann Arbor, Michigan;
- University of Cincinnati Medical Center (US)
- National Institutes of Health (US)
- Tulane University (US)
- VA Medical Center, Section of Endocrinology, University of Cleveland, Cleveland, Ohio;
- State University of New York (US)
- University of Washington (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Calles-Escandón, Jorge
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-01-26
- Volume
- 33
- Issue
- 4
- Pages
- 721-727
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2845012
- OpenAlex
- W2136749671
- Cited by
- 160
- References
- 28
- Citations by year
- 2026: 1 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 6 · 2020: 13 · 2019: 3 · 2018: 7 · 2017: 5 · 2016: 14 · 2015: 20 · 2014: 22 · 2013: 13 · 2012: 10
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tight glycemic control, type 2 diabetes, all-cause mortality, subgroup analysis, HbA1c, aspirin use, cardiovascular risk, ACCORD trial, treatment effect heterogeneity
- MeSH terms
- Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.